HIMS: Hims & Hers Health, Inc. Stock

by  •  • Comments Off on HIMS: Hims & Hers Health, Inc. Stock

SIC 8011 – Offices and Clinics of Doctors of Medicine

Valuation
Market Cap ($M) 6,824.11
Enterprise Value ($M) 6,603.53
Book Value ($M) 476.72
Book Value / Share 2.23
Price / Book 14.31
NCAV ($M) 165.01
NCAV / Share 0.77
Price / NCAV 41.36

Profitability (mra)
Return on Invested Capital (ROIC) 0.26
Return on Assets (ROA) 0.29
Return on Equity (ROE) 0.37

Liquidity (mrq)
Quick Ratio 1.50
Current Ratio 1.79

Balance Sheet (mrq) ($M)
Current Assets 395.83
Assets 707.54
Liabilities 230.82
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1,476.51
Operating Income 66.00
Net Income 126.04
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 251.08
Cash from Investing -19.05
Cash from Financing -107.84

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-12 13G/A Vanguard Group Inc 8.73 0.00
11-07 13G/A BlackRock, Inc. 14.20 92.14
10-25 13D/A Dudum Andrew 11.10 -8.35
05-22 13D/A Institutional Venture Management XVI, LLC 3.60 -41.71

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-24 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-28 5,385,648 19,269,638 27.95
2025-03-27 4,342,689 14,500,101 29.95
2025-03-25 4,781,181 15,740,320 30.38

(click for more detail)

Similar Companies
TDOC – Teladoc Health, Inc.


Financial data and stock pages provided by
Fintel.io